All In Biotech

Drug Trial Radar · NCT05598320

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Mar 3, 2023

Primary completion

Aug 9, 2024

Study completion Aug 13, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.

Conditions

  • Achondroplasia

Interventions

  • Navepegritide (TransCon CNP)Drug

    Once-weekly subcutaneous injection of 100 µg/kg Navepegritide (TransCon CNP)

  • Placebo for Navepegritide (TransCon CNP)Drug

    Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide (TransCon CNP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Growth Velocity (AGV) at Week 52Time frame: At Week 52

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Saint Paul, Minnesota

  • Ascendis Pharma Investigational Site

    Columbia, Missouri

  • Ascendis Pharma Investigational Site

    Houston, Texas

  • Ascendis Pharma Investigational Site

    Madison, Wisconsin

  • Ascendis Pharma Investigational Site

    Parkville, Australia

  • Ascendis Pharma Investigational Site

    Montreal, Canada

  • Ascendis Pharma Investigational Site

    Copenhagen, Denmark

  • Ascendis Pharma Investigational Site

    Dublin, Ireland

  • Ascendis Pharma Investigational Site

    Auckland, New Zealand

  • Ascendis Pharma Investigational Site

    Vitoria-Gasteiz, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.